Oct 16 (Reuters) - Alexion Pharmaceuticals Inc on Wednesday agreed to buy small biotech Achillion Pharmaceuticals Inc in a $930 million deal, to boost its pipeline of rare disease treatments.
Alexion’s offer of $6.30 per share represents a premium of 72.6% to Achillion stock’s close on Tuesday.
The deal is expected to close in the first half of 2020, the companies said. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)
Our Standards: The Thomson Reuters Trust Principles.